Patents by Inventor Thomas Charles Boone
Thomas Charles Boone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130336992Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: August 26, 2013Publication date: December 19, 2013Applicant: AMGEN INC.Inventors: Thomas Charles Boone, Jonathan Daniel Oliner, Eunkyung Lee
-
Publication number: 20130230515Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: November 20, 2012Publication date: September 5, 2013Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Publication number: 20120083442Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: December 2, 2011Publication date: April 5, 2012Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Publication number: 20100330072Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: August 23, 2010Publication date: December 30, 2010Applicant: Amgen Inc.Inventors: HQ Han, Hosung Min, Thomas Charles Boone
-
Publication number: 20090227517Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: January 30, 2009Publication date: September 10, 2009Applicant: Amgen Inc.Inventors: Hq Han, Hosung Min, Thomas Charles Boone
-
Publication number: 20090220491Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: February 10, 2009Publication date: September 3, 2009Applicant: Amgen Inc.Inventors: Hq Han, Hosung Min, Thomas Charles Boone
-
Patent number: 7511012Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: December 19, 2003Date of Patent: March 31, 2009Assignee: Amgen Inc.Inventors: Hq Han, Hosung Min, Thomas Charles Boone
-
Patent number: 7488590Abstract: Pharmacologically active compounds are prepared by (a) selecting at least one peptide that modulates the activity of AGP-3, (b) preparing a gene construct that comprises at least one said selected sequence, and (c) expressing the pharmacologically active compound in which an Fc domain is covalently linked to the selected peptide. The pharmacologic agent can be expressed in E. coli.Type: GrantFiled: August 18, 2003Date of Patent: February 10, 2009Assignee: Amgen Inc.Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone, Jean Marie Gudas
-
Publication number: 20080213277Abstract: The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders.Type: ApplicationFiled: January 30, 2008Publication date: September 4, 2008Applicant: AMGEN INC.Inventors: Barbra Sasu, Mitsuru Hainu, Thomas Charles Boone, Xiao-Juan Bi, Ki Jeong Lee, Tara Arvedson, Aaron Winters, Keegan Cooke, Zeqi Sheng
-
Patent number: 7348162Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.Type: GrantFiled: March 22, 2001Date of Patent: March 25, 2008Assignee: Amgen Inc.Inventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey
-
Patent number: 7008924Abstract: The present invention provides novel VGF polypeptides and selective binding agents. The invention also provides host cells and methods for producing VGF polypeptides. The invention further provides VGF pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, conditions, and disorders associated with VGF polypeptides.Type: GrantFiled: July 19, 2000Date of Patent: March 7, 2006Assignee: Amgen, Inc.Inventors: Hai Yan, Thomas Charles Boone
-
Publication number: 20040181033Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therepeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and other metabolic disorders including diabetes and obesity.Type: ApplicationFiled: December 19, 2003Publication date: September 16, 2004Inventors: Hq Han, Hosung Min, Thomas Charles Boone
-
Publication number: 20040087778Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides.Type: ApplicationFiled: August 29, 2003Publication date: May 6, 2004Applicant: Amgen Inc.Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone
-
Publication number: 20040077022Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides.Type: ApplicationFiled: September 19, 2003Publication date: April 22, 2004Inventors: Ulrich Feige, Chun-Fa Liu, Janet C. Cheetham, Thomas Charles Boone, Jean Marie Gudas
-
Patent number: 6723701Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.Type: GrantFiled: December 19, 2000Date of Patent: April 20, 2004Assignee: Amgen Inc.Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
-
Publication number: 20040071712Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides.Type: ApplicationFiled: August 18, 2003Publication date: April 15, 2004Applicant: Amgen Inc.Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone
-
Publication number: 20040057953Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides.Type: ApplicationFiled: August 29, 2003Publication date: March 25, 2004Applicant: Amgen Inc.Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone
-
Publication number: 20040053845Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides.Type: ApplicationFiled: July 31, 2003Publication date: March 18, 2004Applicant: Amgen Inc.Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone
-
Publication number: 20040044188Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides.Type: ApplicationFiled: June 27, 2003Publication date: March 4, 2004Applicant: Amgen Inc.Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone
-
Publication number: 20030087384Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.Type: ApplicationFiled: August 28, 2002Publication date: May 8, 2003Applicant: Amgen Inc. A Corporation of the State of DelawareInventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey